Does the drug Tolvaptan have any effect on decreasing the total kidney volume in patients with autosomal dominant polycystic kidney disease
Phase 4
- Conditions
- Health Condition 1: Q612- Polycystic kidney, adult type
- Registration Number
- CTRI/2019/11/022099
- Lead Sponsor
- DrAnjana Asokan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
eGFR >25ml/min/1.73m2
Total kidney volume >750 ml
Exclusion Criteria
eGFR <25 ml/min/1.73m2
Total kidney volume <750ml
Atypical cases of polycystic kidney disease
Hepatic diseases (other than hepatic cysts)
Heart failure
Subjects unable to take plenty of fluids
Pregnant and lactating patients
Patient requiring intervention or surgery.
Patients not tolerating tolvaptan.
Need for diuretic use
Patients with advanced diabetes mellitus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage change in total kidney volume at the end of 6 monthsTimepoint: Before initiating treatment and at the end of 6 months
- Secondary Outcome Measures
Name Time Method Percentage change in eGFR at the end of 6 monthsTimepoint: Before initiating treatment and at the end of 6 months